📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Sakar Healthcare Q3 FY26 PAT Surges 126% YoY to ₹10.25 Cr on Strong Oncology Growth
Sakar Healthcare reported a robust 62% YoY revenue growth to ₹70.34 crore for Q3 FY26, driven primarily by its high-margin oncology vertical. Net profit jumped 126% to ₹10.25 crore, supported by operational leverage and a shift toward own-brand exports which now contribute over 70% of revenue. The company has secured 11 marketing authorizations for oncology products in Europe and emerging markets, including Imatinib and Capecitabine. Management has provided a strong outlook, expecting 60-70% growth in the oncology segment for FY27 as more products enter commercialization in regulated markets.
Key Highlights
Revenue from operations grew 62% YoY to ₹70.34 crore in Q3 FY26.
Profit After Tax (PAT) increased by 126% YoY to ₹10.25 crore with EBITDA margins at 26%.
Oncology segment contributed ₹31 crore to Q3 revenue, with ₹19 crore derived from exports.
Received 11 marketing authorizations for oncology products; 10 molecules are currently in tech transfer with Intas/Accord for the EU market.
Management guides for a 60-70% year-on-year growth in the oncology vertical for FY27.
💼 Action for Investors
Investors should closely track the commercialization of the 10 tech-transfer molecules with Intas/Accord, as these represent high-margin opportunities in the European market. The company's transition into a specialized oncology player with EU GMP certification makes it a strong growth candidate in the mid-cap pharma space.
Sakar Healthcare Pivots to High-Margin Oncology with EU-GMP Certified Facility
Sakar Healthcare is transitioning from a contract manufacturer to a vertically integrated oncology specialist with its EU-GMP certified facility in Bavla, Gujarat. The company has developed 55 oncology molecules, with 32 ready for global launch and 11 Marketing Authorizations already granted. Management highlights that oncology formulations offer approximately 2x higher margins compared to general formulations. The strategic roadmap focuses on increasing own-brand exports to 70% of revenue to enhance long-term profitability and brand equity.
Key Highlights
Developed 55 oncology molecules with 32 ready for launch and 11 Marketing Authorizations granted globally.
Oncology segment delivers approximately 2x higher margins versus general pharmaceutical formulations.
Annual production capacity includes 12.3 MT of APIs, 97 million tablets, and 13 million sterile injectable vials.
Strategic shift targeting 70% of revenue from own-brand exports across 60+ countries.
EU-GMP approved Bavla facility enables vertical integration from API to Finished Dosage Form (FDF).
💼 Action for Investors
Investors should track the commercial rollout of the 32 launch-ready oncology molecules as they are key to margin expansion. The successful transition to a high-value oncology-led model could lead to a significant valuation re-rating.
Sakar Healthcare Q3 FY26 PAT Surges 126% YoY to ₹1,025 Lakhs; Revenue Up 62%
Sakar Healthcare reported a stellar Q3 FY26 with revenue growing 62% YoY to ₹7,034 lakhs, driven by its oncology division and EU market demand. Net profit more than doubled, rising 126% YoY to ₹1,025 lakhs, as PAT margins expanded significantly from 10% to 15%. The company's oncology facility received approval as a manufacturing source for Accord Healthcare UK, marking a major milestone for EU exports. With 11 marketing authorizations already secured and over 40 contract discussions ongoing, the company expects accelerated growth in FY27.
Key Highlights
Q3 FY26 Revenue grew 62% YoY to ₹7,034 lakhs, while 9M FY26 Revenue rose 42% to ₹18,064 lakhs
Net Profit (PAT) for the quarter surged 126% YoY to ₹1,025 lakhs with margins expanding from 10% to 15%
EBITDA increased 58% YoY to ₹1,859 lakhs, maintaining a healthy margin of 26%
Secured 11 Marketing Authorizations globally and completed over 50 business contracts for oncology products
Approved as a manufacturing source for Accord Healthcare UK for Imatinib supplies to the EU market
💼 Action for Investors
Investors should view this as a strong growth signal, particularly the margin expansion and the breakthrough into the regulated EU oncology market. Monitor the progress of the 40+ ongoing contract discussions and the ramp-up of EU-linked supplies in FY27.
Sakar Healthcare Q3 FY26 Net Profit Surges 126% YoY to ₹10.25 Cr; Revenue Up 62%
Sakar Healthcare reported a stellar performance for the quarter ended December 31, 2025, with consolidated revenue from operations growing 62% YoY to ₹70.34 crore. Net profit for the quarter more than doubled, reaching ₹10.25 crore compared to ₹4.53 crore in the same period last year. The company's 9-month profit of ₹19.46 crore has already surpassed the full-year FY25 profit of ₹17.50 crore. Operating margins improved significantly, reflected in the EPS jumping from ₹2.08 to ₹4.59 YoY.
Key Highlights
Revenue from operations grew 62% YoY to ₹70.34 crore in Q3 FY26 compared to ₹43.42 crore in Q3 FY25.
Net Profit surged 126% YoY to ₹10.25 crore, with a strong sequential (QoQ) growth of 125%.
9M FY26 Net Profit reached ₹19.46 crore, already exceeding the entire FY25 full-year profit of ₹17.50 crore.
Basic EPS for the quarter increased significantly to ₹4.59 from ₹2.08 in the year-ago quarter.
Total expenses for the quarter stood at ₹59.90 crore, driven primarily by material costs of ₹38.54 crore.
💼 Action for Investors
The company is exhibiting strong growth momentum and significant margin expansion. Investors should maintain a positive outlook while monitoring the sustainability of these growth rates in upcoming quarters.
Sakar Healthcare Q3 PAT Surges 126% YoY to ₹10.25 Cr; Revenue Up 62%
Sakar Healthcare reported a robust performance for Q3 FY2025-26, with revenue from operations growing 62% YoY to ₹70.34 crore. Net profit (PAT) saw a significant jump of 126% YoY, reaching ₹10.25 crore compared to ₹4.53 crore in the same quarter last year. On a sequential basis, PAT more than doubled from ₹4.54 crore in Q2 FY26, indicating strong operational momentum. The company's 9-month total income of ₹182.75 crore has already surpassed the full-year income of FY2024-25.
Key Highlights
Revenue from operations increased by 62% YoY to ₹7034.24 lakh from ₹4341.71 lakh.
Net Profit (PAT) surged by 126% YoY to ₹1024.91 lakh.
Profit Before Tax (PBT) grew by 100% YoY to ₹1095.25 lakh.
Basic EPS improved significantly to ₹4.59 from ₹2.08 in the previous year's quarter.
Total income for the 9-month period reached ₹182.75 crore, exceeding the full FY25 audited income of ₹178.90 crore.
💼 Action for Investors
The company is demonstrating exceptional growth and margin expansion, with 9-month profits already exceeding previous full-year figures. Investors should consider this a strong growth play in the healthcare sector, though they should monitor the sustainability of these high margins in upcoming quarters.
Sakar Healthcare to Supply Imatinib (100mg & 400mg) to EU Market Following EMA Approval
Sakar Healthcare's oncology facility has been approved by the European Medical Agency (EMA) as a manufacturing source for Accord Healthcare's Imatinib (100mg and 400mg) tablets. This approval allows Sakar to cater to the European market, marking the first of nine oncology products planned under the Accord partnership. The company anticipates a positive impact on top-line sales in the upcoming fiscal year due to improved capacity utilization. Sakar is now positioned to supply a total of 12 approved products to international markets.
Key Highlights
EMA approval secured for manufacturing Imatinib 100mg and 400mg film-coated tablets for the EU market.
First of 9 oncology products to be manufactured for Accord Healthcare's European distribution.
Expected to drive top-line sales growth in the coming fiscal year through higher capacity utilization.
Sakar now has a portfolio of 12 approved products ready for overseas supply.
💼 Action for Investors
Investors should view this as a significant milestone for Sakar's export business and monitor the revenue contribution from these EU supplies in upcoming quarterly results.